|
Launch of New-DN Injection with Salmon-Derived Ingredient (Polydeoxyribonucleotide)
2016.05.20
|
|---|
|
Daehan New Pharm launched New-DN Injection, containing Polydeoxyribonucleotide (known as "salmon injection ingredient"), in April. The product was developed primarily by Korea BMI and is jointly marketed by Daehan New Pharm and two other companies. Within one week of launch, the initial batch of orders was fully distributed to the market, including wholesalers and clinics, with the second batch already awaiting supply, indicating a successful release and expected significant contribution to sales.
The overall market for salmon injection ingredients is currently estimated to be around 40 billion KRW but is predicted to exceed 50 billion KRW in 2016 due to the increasing number of companies selling these products.
New-DN Injection, well known for its salmon injection ingredient, has primarily been used as an adjunct therapy for pain relief in anesthesiology and orthopedics. Due to its tissue regeneration effects, it is also used in the skin and beauty sectors in combination with HA fillers, known as “water glow injections.”
Daehan New Pharm is already well recognized in the skin beauty area with products like Luthione Injection and Cindella Injection. Unlike other co-marketing partners, Daehan New Pharm holds confidence that it can lead and expand the therapeutic market for salmon injection ingredients. Current sales data show that about 50% of New-DN Injection’s client base comes from dermatology.
The company plans to achieve sales of over 3 billion KRW for New-DN Injection in 2016 and aims to reach 10 billion KRW in 2017. Leveraging its experience from New-DN Injection, Luthione Injection, and Cindella Injection, Daehan New Pharm plans to expand further into the skin beauty business, including fillers and beauty devices. |


Home